Home › Funds › Palo Alto Investors LP › URGN

Palo Alto Investors LP position in URGN

UROGEN PHARMA LTD · Health Care

Palo Alto Investors LP reported holding 24,500 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$995K, representing 0.15% of its reported portfolio and ranking #49 among its reported holdings. Palo Alto Investors LP has disclosed URGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)24.50K sh
Reported value held$995.43K
Portfolio Weight0.15%
First reportedQ3 2023
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Palo Alto Investors LP's URGN position evolved

Palo Alto Investors LP first disclosed a stake in URGN in Q3 2023 at 24,500 shares (US$343K). The position peaked in Q3 2026 at 24,500 shares, worth US$995K. Across 13 filings, Palo Alto Investors LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 24,500 shares valued at US$995K.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 24.50K $343.25K New
Q4 2023 24.50K $367.50K Hold
Q1 2024 24.50K $367.50K Hold
Q2 2024 24.50K $411.11K Hold
Q3 2024 24.50K $311.15K Hold
Q4 2024 24.50K $260.93K Hold
Q1 2025 24.50K $270.97K Hold
Q2 2025 24.50K $335.65K Hold
Q3 2025 24.50K $488.77K Hold
Q4 2025 24.50K $573.79K Hold
Q1 2026 24.50K $440.51K Hold
Q2 2026 24.50K $901.60K Hold
Q3 2026 24.50K $995.43K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 49 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$184.6M), Kynam Capital Management, LP (US$98.9M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has Palo Alto Investors LP held URGN?

Palo Alto Investors LP has disclosed URGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Palo Alto Investors LP's current position in URGN?

As of Q3 2026, Palo Alto Investors LP holds 24.50K shares of URGN (UROGEN PHARMA LTD), valued at $995.43K, representing 0.15% of its reported portfolio and ranking #49.

Has Palo Alto Investors LP been buying or selling URGN?

In the latest 13F filing (Q3 2026), Palo Alto Investors LP held unchanged its position in URGN. The position peaked in Q3 2026 at 24.50K shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.